Doximity, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $DOCS in the last 7 days.
Washington Trust Bancorp (WASH) rose 5% after beating Q3 2026 estimates. Doximity (DOCS) gained 7.3% following a partnership with Wolters Kluwer. Myriad Genetics (MYGN) surged 22.2% after selling its Prenatal Health unit to Labcorp. Arhaus (ARHS) climbed 6.5% on an upgrade and price target raise. Gartner (IT) increased 4.5% after price target hikes.
Doximity's average price target increased from $30.89 to $31.05, with a range of $18 to $47, according to 19 analysts. This implies a 1% downside from the Oct. 19 closing price. The consensus rating remains 'Buy' among 23 analysts.
Doximity and OpenEvidence, competitors in clinical AI, settled a legal dispute involving allegations of corporate espionage and doctor impersonation. The case was dismissed with prejudice, and both parties agreed to pay their own legal fees. OpenEvidence's monthly active users grew to 703,000 by June 2026, while Doximity partnered with Wolters Kluwer Health.
Recent DOCS coverage spans financial news, regulation and market movers.
In the last 30 days, DOCS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($172K). The most active reporter was Yang Watkin Phoebe L. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strategic partnership fuels bullish sentiment.
Doximity's average price target increased from $30.89 to $31.05, with a range of $18 to $47, according to 19 analysts. This implies a 1% downside from the Oct. 19 closing price. The consensus rating remains 'Buy' among 23 analysts.
Doximity and OpenEvidence, competitors in clinical AI, settled a legal dispute involving allegations of corporate espionage and doctor impersonation. The case was dismissed with prejudice, and both parties agreed to pay their own legal fees. OpenEvidence's monthly active users grew to 703,000 by June 2026, while Doximity partnered with Wolters Kluwer Health.
Settlement removes legal uncertainty, likely supporting a price rise.
The renewal may modestly boost Doximity's visibility and data usage but lacks immediate financial impact.
AlphAI scores every news story that mentions DOCS with an AI model for sentiment and relevance, and aggregates insider trades from Doximity, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Washington Trust Bancorp (WASH) rose 5% after beating Q3 2026 estimates. Doximity (DOCS) gained 7.3% following a partnership with Wolters Kluwer. Myriad Genetics (MYGN) surged 22.2% after selling its Prenatal Health unit to Labcorp. Arhaus (ARHS) climbed 6.5% on an upgrade and price target raise. Gartner (IT) increased 4.5% after price target hikes.
2 min readDoximity's average price target increased from $30.89 to $31.05, with a range of $18 to $47, according to 19 analysts. This implies a 1% downside from the Oct. 19 closing price. The consensus rating remains 'Buy' among 23 analysts.
1 min readDoximity and OpenEvidence, competitors in clinical AI, settled a legal dispute involving allegations of corporate espionage and doctor impersonation. The case was dismissed with prejudice, and both parties agreed to pay their own legal fees. OpenEvidence's monthly active users grew to 703,000 by June 2026, while Doximity partnered with Wolters Kluwer Health.
2 min readRaymond James reiterated an Outperform rating and $38 price target for Doximity (DOCS) after a potential legal settlement was announced. The stock trades at $31.34, below its 52-week high of $71.37. DOCS reported Q1 earnings beating expectations but lowered its EBITDA outlook. Analysts have mixed views on the stock.
2 min readDoximity (DOCS) extended its 13-year partnership with U.S. News to help patients access healthcare services. The collaboration includes physician surveys, hospital rankings, and appointment scheduling. Doximity's network has 3 million members. DOCS stock closed at $30.58, up 0.26%, and is down 0.43% in premarket trading.
1 min readUnity (NYSE:U) beat estimates, stock up 32.1%. Upstart (NASDAQ:UPST) reported 41.7% revenue growth but missed guidance, stock down 20.5%. Dolby (NYSE:DLB) revenue fell 3.3%, stock up 13.4%. Doximity (NYSE:DOCS) revenue up 7.3%, stock up 47.6%. Market focus shifted from AI to geopolitics.
2 min readUpstart (UPST) reported Q2 revenue of $364.7M, up 41.7% YoY, but missed full-year guidance, causing its stock to drop 20.7%. PTC (PTC) saw revenue decline 6.8% YoY to $600M, missing estimates, yet its stock rose 45.8%. Toast (TOST) reported $1.91B in revenue, up 23.1% YoY, beating expectations but missing EBITDA guidance, with its stock down 9.9%.
2 min readUiPath (PATH), monday.com (MNDY), Amplitude (AMPL), Doximity (DOCS), and Sprinklr (CXM) shares rose after a 0.9% increase in August personal consumption expenditures, indicating strong consumer demand. Doximity's volatility and recent performance were highlighted, with the stock down 35.3% year-to-date.
2 min readDoximity Inc. faces a proposed class-action lawsuit from a shareholder alleging the company hid market share losses to competitors and misled investors about its advertising strategy.
2 min readDoximity officer Siddharth Sitaram filed a Rule 144 notice to sell 2,077 shares, valued at $54,043.54, following a stock option exercise. He previously sold 1,770 shares in August and 1,732 shares in July. The company has 127,349,369 shares outstanding.
1 min read
